aluates Reports

$ 0.0

Automative

Global Respiratory Virus Infection Drugs Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-24E5549

Global Respiratory Virus Infection Drugs Market Insights Forecast to 2028

BUY CHAPTERS

Global Respiratory Virus Infection Drugs Market Research Report 2025

Code: QYRE-Auto-24E5549

Report

July 2025

Pages:75

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

GlaxoSmithKline PLC

Merck and Co Inc

Astrazeneca plc

Boehringer Ingelheim International GmbH

F Hoffmann La Roche Ltd

Teva Pharmaceutical Industries Ltd

Sanofi

Chiesi Farmaceutici

Orion Corporation

Cipla Ltd

Respiratory Virus Infection Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Respiratory Virus Infection Drugs Market

The global market for Respiratory Virus Infection Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

North America dominated the global respiratory virus infection drugs market in 2019. The trend is anticipated to continue during the forecast period. Strategies adopted by key players, such as product approvals & launch and mergers & acquisitions, well-established healthcare infrastructure, and early adoption of advanced therapeutics boost the growth of the respiratory virus infection drugs treatment market in the region.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Respiratory Virus Infection Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Virus Infection Drugs.

The Respiratory Virus Infection Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Respiratory Virus Infection Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Respiratory Virus Infection Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Respiratory Virus Infection Drugs Market Report

Report Metric	Details
Report Name	Respiratory Virus Infection Drugs Market
CAGR	5%
Segment by Type	Antibiotics Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) Cough Suppressants Nasal Decongestants Others
Segment by Application	Hospital Pharmacies Drug Stores Retail Pharmacies Clinics Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GlaxoSmithKline plc, Merck and Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, CHIESI Farmaceutici S.p.A., Orion Corporation, Cipla, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Virus Infection Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Respiratory Virus Infection Drugs Market report?

Ans: The main players in the Respiratory Virus Infection Drugs Market are GlaxoSmithKline plc, Merck and Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, CHIESI Farmaceutici S.p.A., Orion Corporation, Cipla, Inc.

What are the Application segmentation covered in the Respiratory Virus Infection Drugs Market report?

Ans: The Applications covered in the Respiratory Virus Infection Drugs Market report are Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics, Others

What are the Type segmentation covered in the Respiratory Virus Infection Drugs Market report?

Ans: The Types covered in the Respiratory Virus Infection Drugs Market report are Antibiotics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Cough Suppressants, Nasal Decongestants, Others

Recommended Reports

Respiratory Virus Drugs

Viral Infection Treatments

Antiviral Vaccines & Diagnostics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Respiratory Virus Infection Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Antibiotics

1.2.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

1.2.4 Cough Suppressants

1.2.5 Nasal Decongestants

1.2.6 Others

1.3 Market by Application

1.3.1 Global Respiratory Virus Infection Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Drug Stores

1.3.4 Retail Pharmacies

1.3.5 Clinics

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Respiratory Virus Infection Drugs Market Perspective (2020-2031)

2.2 Global Respiratory Virus Infection Drugs Growth Trends by Region

2.2.1 Global Respiratory Virus Infection Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Respiratory Virus Infection Drugs Historic Market Size by Region (2020-2025)

2.2.3 Respiratory Virus Infection Drugs Forecasted Market Size by Region (2026-2031)

2.3 Respiratory Virus Infection Drugs Market Dynamics

2.3.1 Respiratory Virus Infection Drugs Industry Trends

2.3.2 Respiratory Virus Infection Drugs Market Drivers

2.3.3 Respiratory Virus Infection Drugs Market Challenges

2.3.4 Respiratory Virus Infection Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Respiratory Virus Infection Drugs Players by Revenue

3.1.1 Global Top Respiratory Virus Infection Drugs Players by Revenue (2020-2025)

3.1.2 Global Respiratory Virus Infection Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Respiratory Virus Infection Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Respiratory Virus Infection Drugs Revenue

3.4 Global Respiratory Virus Infection Drugs Market Concentration Ratio

3.4.1 Global Respiratory Virus Infection Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Respiratory Virus Infection Drugs Revenue in 2024

3.5 Global Key Players of Respiratory Virus Infection Drugs Head office and Area Served

3.6 Global Key Players of Respiratory Virus Infection Drugs, Product and Application

3.7 Global Key Players of Respiratory Virus Infection Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Respiratory Virus Infection Drugs Breakdown Data by Type

4.1 Global Respiratory Virus Infection Drugs Historic Market Size by Type (2020-2025)

4.2 Global Respiratory Virus Infection Drugs Forecasted Market Size by Type (2026-2031)

5 Respiratory Virus Infection Drugs Breakdown Data by Application

5.1 Global Respiratory Virus Infection Drugs Historic Market Size by Application (2020-2025)

5.2 Global Respiratory Virus Infection Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Respiratory Virus Infection Drugs Market Size (2020-2031)

6.2 North America Respiratory Virus Infection Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Respiratory Virus Infection Drugs Market Size by Country (2020-2025)

6.4 North America Respiratory Virus Infection Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Respiratory Virus Infection Drugs Market Size (2020-2031)

7.2 Europe Respiratory Virus Infection Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Respiratory Virus Infection Drugs Market Size by Country (2020-2025)

7.4 Europe Respiratory Virus Infection Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Respiratory Virus Infection Drugs Market Size (2020-2031)

8.2 Asia-Pacific Respiratory Virus Infection Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Respiratory Virus Infection Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Respiratory Virus Infection Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Respiratory Virus Infection Drugs Market Size (2020-2031)

9.2 Latin America Respiratory Virus Infection Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Respiratory Virus Infection Drugs Market Size by Country (2020-2025)

9.4 Latin America Respiratory Virus Infection Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Respiratory Virus Infection Drugs Market Size (2020-2031)

10.2 Middle East & Africa Respiratory Virus Infection Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Respiratory Virus Infection Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Respiratory Virus Infection Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 GlaxoSmithKline plc

11.1.1 GlaxoSmithKline plc Company Details

11.1.2 GlaxoSmithKline plc Business Overview

11.1.3 GlaxoSmithKline plc Respiratory Virus Infection Drugs Introduction

11.1.4 GlaxoSmithKline plc Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.1.5 GlaxoSmithKline plc Recent Development

11.2 Merck and Co., Inc.

11.2.1 Merck and Co., Inc. Company Details

11.2.2 Merck and Co., Inc. Business Overview

11.2.3 Merck and Co., Inc. Respiratory Virus Infection Drugs Introduction

11.2.4 Merck and Co., Inc. Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.2.5 Merck and Co., Inc. Recent Development

11.3 AstraZeneca

11.3.1 AstraZeneca Company Details

11.3.2 AstraZeneca Business Overview

11.3.3 AstraZeneca Respiratory Virus Infection Drugs Introduction

11.3.4 AstraZeneca Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.3.5 AstraZeneca Recent Development

11.4 Boehringer Ingelheim International GmbH

11.4.1 Boehringer Ingelheim International GmbH Company Details

11.4.2 Boehringer Ingelheim International GmbH Business Overview

11.4.3 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Introduction

11.4.4 Boehringer Ingelheim International GmbH Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.4.5 Boehringer Ingelheim International GmbH Recent Development

11.5 F. Hoffmann-La Roche Ltd.

11.5.1 F. Hoffmann-La Roche Ltd. Company Details

11.5.2 F. Hoffmann-La Roche Ltd. Business Overview

11.5.3 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Introduction

11.5.4 F. Hoffmann-La Roche Ltd. Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.5.5 F. Hoffmann-La Roche Ltd. Recent Development

11.6 Teva Pharmaceutical Industries Ltd.

11.6.1 Teva Pharmaceutical Industries Ltd. Company Details

11.6.2 Teva Pharmaceutical Industries Ltd. Business Overview

11.6.3 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Introduction

11.6.4 Teva Pharmaceutical Industries Ltd. Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.6.5 Teva Pharmaceutical Industries Ltd. Recent Development

11.7 Sanofi

11.7.1 Sanofi Company Details

11.7.2 Sanofi Business Overview

11.7.3 Sanofi Respiratory Virus Infection Drugs Introduction

11.7.4 Sanofi Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.7.5 Sanofi Recent Development

11.8 CHIESI Farmaceutici S.p.A.

11.8.1 CHIESI Farmaceutici S.p.A. Company Details

11.8.2 CHIESI Farmaceutici S.p.A. Business Overview

11.8.3 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Introduction

11.8.4 CHIESI Farmaceutici S.p.A. Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.8.5 CHIESI Farmaceutici S.p.A. Recent Development

11.9 Orion Corporation

11.9.1 Orion Corporation Company Details

11.9.2 Orion Corporation Business Overview

11.9.3 Orion Corporation Respiratory Virus Infection Drugs Introduction

11.9.4 Orion Corporation Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.9.5 Orion Corporation Recent Development

11.10 Cipla, Inc.

11.10.1 Cipla, Inc. Company Details

11.10.2 Cipla, Inc. Business Overview

11.10.3 Cipla, Inc. Respiratory Virus Infection Drugs Introduction

11.10.4 Cipla, Inc. Revenue in Respiratory Virus Infection Drugs Business (2020-2025)

11.10.5 Cipla, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

GlaxoSmithKline PLC

Merck and Co Inc

Astrazeneca plc

Boehringer Ingelheim International GmbH

F Hoffmann La Roche Ltd

Teva Pharmaceutical Industries Ltd

Sanofi

Chiesi Farmaceutici

Orion Corporation

Cipla Ltd

List of Tables

Table 1. Global Respiratory Virus Infection Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Antibiotics

Table 3. Key Players of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

Table 4. Key Players of Cough Suppressants

Table 5. Key Players of Nasal Decongestants

Table 6. Key Players of Others

Table 7. Global Respiratory Virus Infection Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Respiratory Virus Infection Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Respiratory Virus Infection Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Respiratory Virus Infection Drugs Market Share by Region (2020-2025)

Table 11. Global Respiratory Virus Infection Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Respiratory Virus Infection Drugs Market Share by Region (2026-2031)

Table 13. Respiratory Virus Infection Drugs Market Trends

Table 14. Respiratory Virus Infection Drugs Market Drivers

Table 15. Respiratory Virus Infection Drugs Market Challenges

Table 16. Respiratory Virus Infection Drugs Market Restraints

Table 17. Global Respiratory Virus Infection Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Respiratory Virus Infection Drugs Market Share by Players (2020-2025)

Table 19. Global Top Respiratory Virus Infection Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Virus Infection Drugs as of 2024)

Table 20. Ranking of Global Top Respiratory Virus Infection Drugs Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Respiratory Virus Infection Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Respiratory Virus Infection Drugs, Headquarters and Area Served

Table 23. Global Key Players of Respiratory Virus Infection Drugs, Product and Application

Table 24. Global Key Players of Respiratory Virus Infection Drugs, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Respiratory Virus Infection Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Respiratory Virus Infection Drugs Revenue Market Share by Type (2020-2025)

Table 28. Global Respiratory Virus Infection Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Respiratory Virus Infection Drugs Revenue Market Share by Type (2026-2031)

Table 30. Global Respiratory Virus Infection Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Respiratory Virus Infection Drugs Revenue Market Share by Application (2020-2025)

Table 32. Global Respiratory Virus Infection Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Respiratory Virus Infection Drugs Revenue Market Share by Application (2026-2031)

Table 34. North America Respiratory Virus Infection Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Respiratory Virus Infection Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Respiratory Virus Infection Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Respiratory Virus Infection Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Respiratory Virus Infection Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Respiratory Virus Infection Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Respiratory Virus Infection Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Respiratory Virus Infection Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Respiratory Virus Infection Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Respiratory Virus Infection Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Respiratory Virus Infection Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Respiratory Virus Infection Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Respiratory Virus Infection Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Respiratory Virus Infection Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Respiratory Virus Infection Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 49. GlaxoSmithKline plc Company Details

Table 50. GlaxoSmithKline plc Business Overview

Table 51. GlaxoSmithKline plc Respiratory Virus Infection Drugs Product

Table 52. GlaxoSmithKline plc Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 53. GlaxoSmithKline plc Recent Development

Table 54. Merck and Co., Inc. Company Details

Table 55. Merck and Co., Inc. Business Overview

Table 56. Merck and Co., Inc. Respiratory Virus Infection Drugs Product

Table 57. Merck and Co., Inc. Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 58. Merck and Co., Inc. Recent Development

Table 59. AstraZeneca Company Details

Table 60. AstraZeneca Business Overview

Table 61. AstraZeneca Respiratory Virus Infection Drugs Product

Table 62. AstraZeneca Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 63. AstraZeneca Recent Development

Table 64. Boehringer Ingelheim International GmbH Company Details

Table 65. Boehringer Ingelheim International GmbH Business Overview

Table 66. Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Product

Table 67. Boehringer Ingelheim International GmbH Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 68. Boehringer Ingelheim International GmbH Recent Development

Table 69. F. Hoffmann-La Roche Ltd. Company Details

Table 70. F. Hoffmann-La Roche Ltd. Business Overview

Table 71. F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Product

Table 72. F. Hoffmann-La Roche Ltd. Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 73. F. Hoffmann-La Roche Ltd. Recent Development

Table 74. Teva Pharmaceutical Industries Ltd. Company Details

Table 75. Teva Pharmaceutical Industries Ltd. Business Overview

Table 76. Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Product

Table 77. Teva Pharmaceutical Industries Ltd. Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 78. Teva Pharmaceutical Industries Ltd. Recent Development

Table 79. Sanofi Company Details

Table 80. Sanofi Business Overview

Table 81. Sanofi Respiratory Virus Infection Drugs Product

Table 82. Sanofi Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 83. Sanofi Recent Development

Table 84. CHIESI Farmaceutici S.p.A. Company Details

Table 85. CHIESI Farmaceutici S.p.A. Business Overview

Table 86. CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Product

Table 87. CHIESI Farmaceutici S.p.A. Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 88. CHIESI Farmaceutici S.p.A. Recent Development

Table 89. Orion Corporation Company Details

Table 90. Orion Corporation Business Overview

Table 91. Orion Corporation Respiratory Virus Infection Drugs Product

Table 92. Orion Corporation Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 93. Orion Corporation Recent Development

Table 94. Cipla, Inc. Company Details

Table 95. Cipla, Inc. Business Overview

Table 96. Cipla, Inc. Respiratory Virus Infection Drugs Product

Table 97. Cipla, Inc. Revenue in Respiratory Virus Infection Drugs Business (2020-2025) & (US$ Million)

Table 98. Cipla, Inc. Recent Development

Table 99. Research Programs/Design for This Report

Table 100. Key Data Information from Secondary Sources

Table 101. Key Data Information from Primary Sources

Table 102. Authors List of This Report

List of Figures

Figure 1. Respiratory Virus Infection Drugs Picture

Figure 2. Global Respiratory Virus Infection Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Respiratory Virus Infection Drugs Market Share by Type: 2024 VS 2031

Figure 4. Antibiotics Features

Figure 5. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) Features

Figure 6. Cough Suppressants Features

Figure 7. Nasal Decongestants Features

Figure 8. Others Features

Figure 9. Global Respiratory Virus Infection Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Respiratory Virus Infection Drugs Market Share by Application: 2024 VS 2031

Figure 11. Hospital Pharmacies Case Studies

Figure 12. Drug Stores Case Studies

Figure 13. Retail Pharmacies Case Studies

Figure 14. Clinics Case Studies

Figure 15. Others Case Studies

Figure 16. Respiratory Virus Infection Drugs Report Years Considered

Figure 17. Global Respiratory Virus Infection Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 18. Global Respiratory Virus Infection Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 19. Global Respiratory Virus Infection Drugs Market Share by Region: 2024 VS 2031

Figure 20. Global Respiratory Virus Infection Drugs Market Share by Players in 2024

Figure 21. Global Top Respiratory Virus Infection Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Virus Infection Drugs as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Respiratory Virus Infection Drugs Revenue in 2024

Figure 23. North America Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. North America Respiratory Virus Infection Drugs Market Share by Country (2020-2031)

Figure 25. United States Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Canada Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Respiratory Virus Infection Drugs Market Share by Country (2020-2031)

Figure 29. Germany Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Respiratory Virus Infection Drugs Market Share by Region (2020-2031)

Figure 37. China Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Japan Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. South Korea Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. India Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Australia Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Respiratory Virus Infection Drugs Market Share by Country (2020-2031)

Figure 45. Mexico Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Brazil Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Respiratory Virus Infection Drugs Market Share by Country (2020-2031)

Figure 49. Turkey Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. UAE Respiratory Virus Infection Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. GlaxoSmithKline plc Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 53. Merck and Co., Inc. Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 54. AstraZeneca Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 55. Boehringer Ingelheim International GmbH Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 56. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 57. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 58. Sanofi Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 59. CHIESI Farmaceutici S.p.A. Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 60. Orion Corporation Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 61. Cipla, Inc. Revenue Growth Rate in Respiratory Virus Infection Drugs Business (2020-2025)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Prescription Respiratory Drugs Market Research Report 2024

Global Respiratory Infection Diagnostic Market Research Report 2024

Respiratory Syncytial Virus RSV Infections Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Respiratory Syncytial Virus Therapeutic Drugs Market Research Report 2024

Respiratory Antivirals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Respiratory Virus Vaccines Market Research Report 2024

Global Rhinovirus Infections Drug Market Research Report 2024

Respiratory Viruses Tests Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Respiratory Antiviral Treatment Market Research Report 2024

Global Infectious Respiratory Disease Diagnostics Market Research Report 2025

Viral Pneumonia Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Respiratory Syncytial Virus Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Drugs for Respiratory Diseases Market Research Report 2024

PCR For Respiratory Infection Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Pediatric Respiratory Syncytial Virus Infection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Respiratory Disorders Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Eye Infection Drugs Market Insights Forecast to 2030

Swine Respiratory Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Respiratory Disorders Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions